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Introduction
• Multiple myeloma (MM) is a malignancy of plasma cells that accounts for 
approximately 1 to 2 percent of all cancers and about 17% of all 
hematologic malignancies.
• Plasma cells normally produce antibodies and provide a defense 
mechanism for the body to fight infections. 
• Antibodies typically consist of two heavy chains (IgG, IgA, IgM, IgD and 
IgE) and two light chains (kappa and lambda).
• Most cases of MM have malignant plasma cells producing monoclonal 
(M) proteins, most common being IgG about 52% of the time (1).
• Only about 2% of these myeloma cases were also found to secrete more 
than one paraprotein and classified as biclonal/biphenotypic plasma cell 
myeloma (2).
• Here we report a case of a woman who presented with lower back pain 
that was found to have biphenotypic multiple myeloma with a 
coexpression of kappa and lambda light chains.
Case Presentation
• 52-year-old African American female was admitted with a chief complaint 
of lower back pain for a 3-4 months duration.
• PMH: hypertension, peptic ulcer disease and gastroesophageal reflux 
disease
• Labs were significant for elevated serum creatinine of 6.13 and serum 
calcium of 12.5, hemoglobin of 8.4.
• Renal ultrasound showed no hydronephrosis or renal calculi, increased 
bilateral cortical echogenicity, indicative of some degree of underlying 
chronic kidney disease. 
• SPEP showed positive free lambda (23993), positive free kappa light 
chain (43.2) normal IgG and IgA ratio, low IgM (25). 
• Urinalysis was significant of 100+ protein and urine protein to creatinine 
ratio consistent with 11.97 grams 
• Bone Survey showed heterogenous appearance of the right humerus 
with scattered ill-defined lytic lesions. Possible ill-defined lytic lesions are 
seen at the proximal left tibia. There was a lytic lesion at the proximal left 
radius.
• Treated with dexamethasone for multiple myeloma and pamidronic acid 
for hypercalcemia with a resolution of serum calcium level to 8.5mg/dL.
• Patient also required hemodialysis for her acute renal failure.
Pathology Discussion
• In older patients presenting with lower back pain and acute renal failure, 
the diagnosis of multiple myeloma should be on the differential
• MM the leading cause of malignancy induced ESRD requiring dialysis. 
• The kidneys metabolizes light chain proteins but Ig and heavy chains do 
not pass through the glomerular filtration barriers.
• Light chains that are filtered are reabsorbed by proximal tubular cells and 
catabolized by lysozymal enzymes, normally this process is very efficient.
• When the burden of light chains exceeds the absorption capacity of the 
tubules, light chains spill into the urine (3).
• Free light chains enter proximal tubule cells and trigger apoptosis and 
inflammation (4).
• Free light chains bind to Tamm-Horsfall protein to form casts which result 
in tubular atrophy, interstitial inflammation and fibrosis leading to renal 
failure 
Treatment Options
• Early diagnosis and initiation of therapy is the best treatment 
• MM patients requiring dialysis have a higher mortality than other causes 
of ESRD with a greater than 85% mortality within 2 years (5).
• Pharmacologic Therapy-Bortezomib-based therapy, especially triple drug 
therapy (thalidomide, dexamethasone and bortezomib) has improved 
survival of patients with mild to moderately reduced kidney function and 
those requiring dialysis. 
• Plasmapheresis-removing light chains from plasma leading to less being 
filtered by the kidney and causing less damage. Studies have shown 
mixed results with no clear evidence of mortality benefit. 
• Stem cell transplantation (SCT)-potentially curative for a small number of 
patients. Interesting renal failure may prevent patient’s them from 
qualifying for SCT, one of the disease’s most effective treatments (6).
• Kidney transplant-clear curative option for patients with MM and ESRD
References
1. Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group Recommendations for 
the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol. 2016;34(13):1544-1557. 
doi:10.1200/JCO.2015.65.0044
2. Jiwani S, Bornhost J, Alapat D. Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a 
coexpression of kappa and lambda light chains. Int J Clin Exp Pathol. 2015;8(7):8536-8544. Published 2015 
Jul 1.
3. Fang, Leslie S. Light Chain Nephropathy. Kidney Inter. 1985: 27:582-592
4. Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple 
myeloma. Nat Rev Nephrol. 2011;8(1):43-51. Published 2011 Nov 1. doi:10.1038/nrneph.2011.168
5. Reule S, Sexton DJ, Solid CA, Chen SC, Foley RN. ESRD due to Multiple Myeloma in the United States, 
2001-2010. J Am Soc Nephrol. 2016;27(5):1487-1494. doi:10.1681/ASN.2014090876
6. Heher EC, Rennke HG, Laubach JP, Richardson PG. Kidney disease and multiple myeloma. Clin J Am Soc 
Nephrol. 2013;8(11):2007-2017. doi:10.2215/CJN.12231212
Multiple Myeloma with Dual Expression of Kappa and Lambda Light Chains 
Monica Patel D.O, Akash Patel D.O, Yvette Wang D.O
Rowan University School of Osteopathic Medicine, Stratford NJ, Jefferson Health New Jersey, Swell NJ
Department of  Internal Medicine
Figures
• Figure 1 and 2: Renal biopsy with tubular atrophy and interstitial fibrosis
• Figure 3: Immunofluorescence staining for Kappa
• Figure 4: Immunofluorescence staining for Lambda
